

Table S2: parameters used in the model

Parameters of epidemic among HIV-positive MSM	Range [source/rationale]
Annual new sexual partners	[Calibrated]
<i>Highest risk group</i>	20-100
<i>Risk group 2</i>	5-15
<i>Risk group 3</i>	1-4
<i>Risk group 4</i>	0.1 – 0.9
Proportion per risk group	[Calibrated]
<i>Highest risk group</i>	0.01 – 0.14
<i>Risk group 2</i>	0.02 - -0.2
<i>Risk group 3</i>	0-0.3
<i>Risk group 4</i>	0.4-0.9
Rate of assortative mixing	0-0.8 [Calibrated]
Patients in stage F3, F4 in 2002	10%-30% [Calibrated]
Life Expectancy and mortality	
Life expectancy HIV-infected men CD4>350	80 years [1]
Life expectancy HIV/HCV co- infected (F0-F3stage)	80 years
Life expectancy HIV/HCV co-infected compensated cirrhosis	0.024-0.055 per year [2]
Life expectancy HIV/HCV decompensated cirrhosis	0.019-0.35 per year [2]
Disease progression	
F0 to F1	0.098 – 0.122, per year [3]
F1 to F2	0.095 – 0.140, per year [3]
F2 to F3	0.097 – 0.159, per year [3]
F3 to Compensated cirrhosis	0.098 – 0.135, per year [3]
Compensated to decompensated cirrhosis	0.029 – 0.063, per year [2]
Compensated to decompensated cirrhosis	0.029 – 0.063, per year [2]
Cirrhosis to Hepatocellular carcinoma	0.01 – 0.03, per year [4]
Transplantations	0 per year
Additional cost to delayed treatment stage	

Parameters of epidemic among HIV-positive MSM	Range [source/rationale]
Cost of HCC (including hospitalization, treatment, surgery and care until death)	€67.591 – €233.573 per patient [5, 6]

1. May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, *et al.* Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. *Aids* 2014, **28**:1193-1202.
2. Lopez-Dieguez M, Montes ML, Pascual-Pareja JF, Quereda C, Von Wichmann MA, Berenguer J, *et al.* The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. *Aids* 2011, **25**:899-904.
3. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. *Aids* 2008, **22**:1979-1991.
4. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. *Gastroenterology* 2004, **127**:S35-50.
5. Tapper EB, Catana AM, Sethi N, Mansuri D, Sethi S, Vong A, *et al.* Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis. *Cancer* 2016, **122**:852-858.
6. Baran RW, Samp JC, Walker DR, Smeeding JE, Young JW, Kleinman NL, *et al.* Costs and absence of HCV-infected employees by disease stage. *J Med Econ* 2015, **18**:691-703.